Skip Navigation


NDT Advance Access originally published online on April 6, 2005
Nephrology Dialysis Transplantation 2005 20(6):1032-1034; doi:10.1093/ndt/gfh803
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/6/1032    most recent
gfh803v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Filler, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Filler, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Editorial Comment

How should microemulsified Cyclosporine A (Neoral®) therapy in patients with nephrotic syndrome be monitored?

Guido Filler

Department of Pediatrics, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada

Correspondence and offprint requests to: Guido Filler, Division of Nephrology, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario K1H 8L1, Canada. Email: filler@cheo.on.ca

Keywords: Cyclosporine A; Sandimmune Neoral; Nephrotic syndrome; Steroid-resistant nephrotic syndrome; Pharmacokinetics

The first 10% of the full text of this article appears below.



   Introduction
 
Cyclosporine A (CyA) has been used empirically for almost two decades in the treatment of severe forms of idiopathic nephrotic syndrome (NS), in both children and adults [1]. The mechanism of CyA's action remains unclear. It may be related to immunosuppressive or haemodynamic properties, or have an effect on heparan sulfate, the main component of the glomerular charge barrier [2]. Initially, the therapy was performed with ‘classic’ Cyclosporine (Sandimmune®). Because of substantial inter- and intra-patient variability and a narrow therapeutic window, therapeutic drug monitoring of Cyclosporine therapy is mandatory [3,4]. With ‘classic’ CyA, trough level monitoring was recommended.

In the mid-1990s a microemulsified (ME) formulation of Cyclosporine (Neoral®) became available and many patients were converted because of . . . [Full Text of this Article]



   Pharmacokinetics of CyA ME in patients with NS
 


   Uncertainty about the target AUC and target C2 concentrations
 


   Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
D. Xiaoli and F. Qiang
Population Pharmacokinetic Study of Cyclosporine in Patients With Nephrotic Syndrome
J. Clin. Pharmacol., July 1, 2009; 49(7): 782 - 788.
[Abstract] [Full Text] [PDF]